1. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study 
Tara R. Semenkovich, MD, MPHS, Melanie Subramanian, MD, Yan Yan, MD, PhD, Wayne L. Hofstetter, MD, Arlene M. Correa, PhD, Stephen D. Cassivi, MD, MSc, Matthew L. Inra, MD, Brendon M. Stiles, MD, Nasser K. Altorki, MD, Andrew C. Chang, MD, Alexander A. Brescia, MD, Gail E. Darling, MD, Frances Allison, BSc, Stephen R. Broderick, MD, MPHS, Eric W. Etchill, MD, MPH, Felix G. Fernandez, MD, MSc, Ray K. Chihara, MD, PhD, Virginia R. Litle, MD, Juan A. Muñoz-Largacha, MD, Benjamin D. Kozower, MD, MPH, Varun Puri, MD, MSCI, Bryan F. Meyers, MD, MPH 
The Annals of Thoracic Surgery 
Volume 108, Issue 3, Pages (September 2019)
DOI: /j.athoracsur
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

2. Figure 1
Consolidated Standards of Reporting Trials diagram. Adjuvant treatment (Adj Tx) was defined as chemotherapy, radiotherapy, or both, given within 6 months of surgery.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

3. Figure 2
Kaplan-Meier analysis of overall survival by adjuvant treatment status. Median (95% confidence limits [CL]; shaded areas) survival for the adjuvant treatment group was 2.6 (95% CL, 2.3 and 3.4 years) vs 2.3 years (95% CL, 2.0 and 2.5 years) for the no adjuvant treatment group.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

4. Figure 3
Kaplan-Meier analysis of overall survival by adjuvant treatment status, stratified by pathologic stage. Median survival estimates with the 95% confidence limits (CL; shaded areas) are shown. (A) Stage IIB: adjuvant, 4.2 years (95% CL, 3.0 and unknown years) vs no adjuvant, 3.3 years (95% CL, 2.9 and 4.0 years). (B) Stage IIIA: adjuvant, 3.4 years (95% CL, 2.4 and 4.1 years) vs no adjuvant, 2.4 years (95% CL, 2.1 and 2.8 years). (C) Stage IIIB: adjuvant, 1.8 years (95% CL, 1.3 and 3.2 years) vs no adjuvant, 1.9 years (95% CL, 1.7 and 2.2 years). (D) Stage IIIC: adjuvant, 1.6 years (95% CL, 1.1 and 2.1 years) vs no adjuvant: 1.1 years (95% CL, 0.9 and 1.4 years).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

5. Supplemental Figure 1
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions

6. Supplemental Figure 2
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions